Dual Antagonist vs Monoclonal Antibody — Immunology Deal Terms Comparison
Market Analysis
In immunology, Dual Antagonist and Monoclonal Antibody represent two of the most actively transacted modalities. At Phase 2, Dual Antagonist deals carry a median total deal value of $3.2B with $606M upfront, compared to $2.5B total value and $480M upfront for Monoclonal Antibody. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Dual Antagonist development milestones average $511M versus $405M for Monoclonal Antibody. Commercial milestones are $1.1B for Dual Antagonist and $911M for Monoclonal Antibody. Royalty rates range from 14.2%-23.7% for Dual Antagonist and 13.2%-22.1% for Monoclonal Antibody.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Dual Antagonist and Monoclonal Antibody deal terms compare in immunology?
Which modality commands higher royalty rates: Dual Antagonist or Monoclonal Antibody?
How do milestone structures differ between Dual Antagonist and Monoclonal Antibody?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.